Scholar Rock Holding Corp (SRRK) Stock Price, Quote & News

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that loca...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 259 3860

Website: www.scholarrock.com

Address:

301 Binney Street, 3rd Floor, Cambridge, United States

Tdorsey1776 Mar. 26 at 12:39 PM

$SRRK $70+ buyout before year end? M&A highly likely. GLTA

1 · Reply

Whiskeyunderthebed Mar. 25 at 12:38 PM

$SRRK my $TERN got purchased today by $MRK- this could be the next one to fall to Roche.

0 · Reply

Whiskeyunderthebed Mar. 24 at 1:43 PM

$SRRK they really want to take this back down to $40. It is more than ever de risked now.

0 · Reply

Tdorsey1776 Mar. 20 at 7:50 PM

$SRRK Moved up the M&A list

0 · Reply

IN0V8 Mar. 20 at 4:13 PM

$SRRK Buy Leerink Partners raises price to $61 from $50

0 · Reply

Haiderss Mar. 20 at 12:54 PM

$SRRK Leerink Partners raises price target to $61 from $50.

0 · Reply

NorthStarStats Mar. 20 at 12:36 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. Scores perking up a little bit; Hopefully it is a good sign: $SRRK Score 98, $JBL Score 95, $FFIV Score 70, $DAY Score 70, $DOC Score 70

0 · Reply

cheating_stock_investor Mar. 20 at 3:06 AM

$SRRK wont be long until rumors come back that they will be acquired as competitors like genetech pulled their competing drug from trials as this will be first of kind in its space with very good results. https://www.investing.com/news/analyst-ratings/truist-reiterates-buy-on-scholar-rock-stock-after-roche-halts-rival-drug-93CH-4572049 With the delay in approval and uncertainties with manufacturing this could be an exit for the company before they need to raise more capital to continue other drugs in their pipeline.

0 · Reply

Whiskeyunderthebed Mar. 19 at 11:49 PM

$SRRK I smelled something when I wrote at 2:00pm this afternoon on "breaking news"- the ticker went north in like 1 minute on shear volume. These clowns -meaning "hedge funds" drove the price under $40 before hand to scare weak hands out as they had inside information on how Genetech trial would utlimately go. This is what we are playing against being a retail trader.

1 · Reply

Tdorsey1776 Mar. 19 at 11:28 PM

$SRRK Blockbuster.... $75-80 eoy. Glta

0 · Reply

Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating

Mar 13, 2026, 4:15 PM EDT - 16 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 12, 2026, 11:52 AM EDT - 17 days ago

Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 3, 2026, 4:42 PM EST - 26 days ago

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 3:26 PM EST - 26 days ago

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 7:00 AM EST - 27 days ago

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 18, 2026, 8:00 AM EST - 5 weeks ago

Scholar Rock to Present at Upcoming Investor Conferences

Feb 10, 2026, 8:00 AM EST - 6 weeks ago

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Jan 12, 2026, 1:15 PM EST - 2 months ago

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

Scholar Rock Highlights 2026 Strategic Priorities

Jan 5, 2026, 11:59 PM EST - 2 months ago

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

Jan 5, 2026, 8:00 AM EST - 2 months ago

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 3:33 PM EST - 4 months ago

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 14, 2025, 2:01 PM EST - 4 months ago

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 4 months ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 3:05 PM EST - 4 months ago

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

CARS CHH HIMS LCID MPT NOG SPHR

Nov 10, 2025, 11:28 AM EST - 4 months ago

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Nov 4, 2025, 8:00 AM EST - 5 months ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Sep 23, 2025, 5:02 PM EDT - 6 months ago

Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions

Sep 23, 2025, 11:32 AM EDT - 6 months ago

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Sep 23, 2025, 8:16 AM EDT - 6 months ago

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

FLY

Sep 23, 2025, 7:12 AM EDT - 6 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:00 AM EDT - 6 months ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Aug 14, 2025, 8:00 AM EDT - 8 months ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 6, 2025, 11:33 PM EDT - 8 months ago

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Jul 21, 2025, 8:00 AM EDT - 9 months ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jun 24, 2025, 6:25 PM EDT - 9 months ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 18, 2025, 10:47 AM EDT - 10 months ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

LLY

Jun 18, 2025, 7:33 AM EDT - 10 months ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:12 AM EDT - 10 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:00 AM EDT - 10 months ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

May 28, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 12:30 PM EDT - 11 months ago

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 11 months ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 7, 2025, 8:00 AM EDT - 11 months ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Apr 28, 2025, 6:50 AM EDT - 1 year ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Mar 25, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 17, 2025, 12:21 PM EDT - 1 year ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 27, 2025, 1:23 PM EST - 1 year ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 25, 2025, 4:15 PM EST - 1 year ago

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 21, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 10, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Tdorsey1776 Mar. 26 at 12:39 PM

$SRRK $70+ buyout before year end? M&A highly likely. GLTA

1 · Reply

Whiskeyunderthebed Mar. 25 at 12:38 PM

$SRRK my $TERN got purchased today by $MRK- this could be the next one to fall to Roche.

0 · Reply

Whiskeyunderthebed Mar. 24 at 1:43 PM

$SRRK they really want to take this back down to $40. It is more than ever de risked now.

0 · Reply

Tdorsey1776 Mar. 20 at 7:50 PM

$SRRK Moved up the M&A list

0 · Reply

IN0V8 Mar. 20 at 4:13 PM

$SRRK Buy Leerink Partners raises price to $61 from $50

0 · Reply

Haiderss Mar. 20 at 12:54 PM

$SRRK Leerink Partners raises price target to $61 from $50.

0 · Reply

NorthStarStats Mar. 20 at 12:36 PM

0 · Reply

cheating_stock_investor Mar. 20 at 3:06 AM

0 · Reply

Whiskeyunderthebed Mar. 19 at 11:49 PM

1 · Reply

Tdorsey1776 Mar. 19 at 11:28 PM

$SRRK Blockbuster.... $75-80 eoy. Glta

0 · Reply

Tdorsey1776 Mar. 19 at 9:01 PM

$SRRK Lets go!! Raise those price targets pronto!!!

0 · Reply

Haiderss Mar. 19 at 8:34 PM

$SRRK upward analyst estimate revisions inevitable

0 · Reply

Unchanged Mar. 19 at 8:21 PM

$SRRK What a difference a day makes.

0 · Reply

Whiskeyunderthebed Mar. 19 at 7:59 PM

$SRRK it's safe to buy even more now.

0 · Reply

Tdorsey1776 Mar. 19 at 7:42 PM

$SRRK This is why you cant snooze on SRRK!!

0 · Reply

Tdorsey1776 Mar. 19 at 7:41 PM

$SRRK Higher!!!!!

0 · Reply

Jonita Mar. 19 at 7:36 PM

$SRRK 💣💣💣

0 · Reply

notreload_ai Mar. 19 at 7:29 PM

Roche halts emugrobart development, clearing path for $SRRK apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential. https://notreload.xyz/scholar-rock-surges-as-roche-drops-sma-drug-competitor/

1 · Reply

Whiskeyunderthebed Mar. 19 at 6:59 PM

$SRRK HUGE!

0 · Reply

DonCorleone77 Mar. 19 at 6:54 PM

$SRRK $RHHBY Cantor sees Scholar Rock dominating SMA market after Genentech news Cantor Fitzgerald analyst Eric Schmidt says Roche's (RHHBY) Genentech sent a letter today to the spinal muscular atrophy community that included an update on the development of emugrobart, an anti-myostatin antibody. According to the letter, Genentech made the decision not to advance emugrobart. Cantor says emugrobart was trailing Scholar Rock's (SRRK) apitegromab in development by several years, and "offered little in the way of differentiation." The firm now expects apitegromab to have "near complete market share" as the lone muscle-building therapy for SMA patients. It continues to view apitegromab's FDA approval as a likely 2026 event. The firm sees multi-billion dollar potential for the drug and notes Scholar Rock continues to be a top pick.

1 · Reply

topstockalerts Mar. 19 at 6:31 PM

$SRRK tends to react to catalysts, otherwise drifts. One headline and it can wake up fast.

1 · Reply

Quantumup Mar. 19 at 6:30 PM

Cantor reiterated $SRRK Top Pick; Overweight $RHHBY $BIIB LLY $NVO IONS $PTCT Here's what Cantor said: https://x.com/Quantumup1/status/2034697600415260772?s=20

0 · Reply

Market Cap	4.89B
Revenue (ttm)	0.00
Net Income (ttm)	-377.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.41

Volume	1,056,900
Avg Vol	1,243,384
Day's Range	N/A - N/A
Shares Out	114.88M
Stochastic %K	42%
Beta	0.70
Analysts	Strong Sell
Price Target	$56.07